Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770

Cystic fibrosis (CF), the most common inherited disease in Caucasians, is caused by mutations in CFTR, the most frequent of which is F508del. F508del causes ER retention and degradation of the mutant CFTR protein, but also defective channel gating and decreased half-life at the plasma membrane. Desp...

Full description

Bibliographic Details
Main Authors: Ana M. Matos, Peter Jordan, Paulo Matos
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-12-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fmolb.2021.812101/full
_version_ 1819320183993401344
author Ana M. Matos
Ana M. Matos
Peter Jordan
Peter Jordan
Paulo Matos
Paulo Matos
author_facet Ana M. Matos
Ana M. Matos
Peter Jordan
Peter Jordan
Paulo Matos
Paulo Matos
author_sort Ana M. Matos
collection DOAJ
description Cystic fibrosis (CF), the most common inherited disease in Caucasians, is caused by mutations in CFTR, the most frequent of which is F508del. F508del causes ER retention and degradation of the mutant CFTR protein, but also defective channel gating and decreased half-life at the plasma membrane. Despite the recent successes with small-molecule CFTR modulator drugs, the folding-corrector/gating-potentiator drug combinations approved for CF individuals carrying F508del-CFTR have sometimes produced severe side effects. Previously, we showed that a prolonged, 15-days treatment of polarized bronchial epithelial monolayers with the VX-809+VX-770 combination resulted in epithelial dedifferentiation effects that we found were caused specifically by VX-809. Moreover, prolonged VX-770 exposure also led to the destabilization of VX-809-rescued F508del-CFTR. Notably, co-treatment with the physiological factor HGF prevented VX-809-mediated epithelial differentiation and reverted the destabilizing effect of VX-770 on VX-809-rescued CFTR. Here, we show that prolonged treatment with VX-661, a second-generation corrector developed based on VX-809 structure, does not perturb epithelial integrity of polarized bronchial epithelial monolayers. Yet, its efficacy is still affected by co-exposure to VX-770, the potentiator present in all VX-661-containing combination therapies approved in the United States and Europe for treatment of F508del-CFTR carriers. Importantly, we found that co-treatment with HGF still ameliorated the impact of VX-770 in F508del-CFTR functional rescue by VX-661, without increasing cell proliferation (Ki-67) or altering the overall expression of epithelial markers (ZO-1, E-cadherin, CK8, CK18). Our findings highlight the importance of evaluating the cellular effects of prolonged exposure to CFTR modulators and suggest that the benefits of adding HGF to current combination therapies should be further investigated.
first_indexed 2024-12-24T11:15:32Z
format Article
id doaj.art-2fe36a86ae4b45e790ee1120460d183c
institution Directory Open Access Journal
issn 2296-889X
language English
last_indexed 2024-12-24T11:15:32Z
publishDate 2021-12-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Molecular Biosciences
spelling doaj.art-2fe36a86ae4b45e790ee1120460d183c2022-12-21T16:58:23ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2021-12-01810.3389/fmolb.2021.812101812101Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770Ana M. Matos0Ana M. Matos1Peter Jordan2Peter Jordan3Paulo Matos4Paulo Matos5Departamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, PortugalBioISI-Biosystems and Integrative Sciences Institute, Faculdade de Ciências da Universidade de Lisboa, Lisboa, PortugalDepartamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, PortugalBioISI-Biosystems and Integrative Sciences Institute, Faculdade de Ciências da Universidade de Lisboa, Lisboa, PortugalDepartamento de Genética Humana, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, PortugalBioISI-Biosystems and Integrative Sciences Institute, Faculdade de Ciências da Universidade de Lisboa, Lisboa, PortugalCystic fibrosis (CF), the most common inherited disease in Caucasians, is caused by mutations in CFTR, the most frequent of which is F508del. F508del causes ER retention and degradation of the mutant CFTR protein, but also defective channel gating and decreased half-life at the plasma membrane. Despite the recent successes with small-molecule CFTR modulator drugs, the folding-corrector/gating-potentiator drug combinations approved for CF individuals carrying F508del-CFTR have sometimes produced severe side effects. Previously, we showed that a prolonged, 15-days treatment of polarized bronchial epithelial monolayers with the VX-809+VX-770 combination resulted in epithelial dedifferentiation effects that we found were caused specifically by VX-809. Moreover, prolonged VX-770 exposure also led to the destabilization of VX-809-rescued F508del-CFTR. Notably, co-treatment with the physiological factor HGF prevented VX-809-mediated epithelial differentiation and reverted the destabilizing effect of VX-770 on VX-809-rescued CFTR. Here, we show that prolonged treatment with VX-661, a second-generation corrector developed based on VX-809 structure, does not perturb epithelial integrity of polarized bronchial epithelial monolayers. Yet, its efficacy is still affected by co-exposure to VX-770, the potentiator present in all VX-661-containing combination therapies approved in the United States and Europe for treatment of F508del-CFTR carriers. Importantly, we found that co-treatment with HGF still ameliorated the impact of VX-770 in F508del-CFTR functional rescue by VX-661, without increasing cell proliferation (Ki-67) or altering the overall expression of epithelial markers (ZO-1, E-cadherin, CK8, CK18). Our findings highlight the importance of evaluating the cellular effects of prolonged exposure to CFTR modulators and suggest that the benefits of adding HGF to current combination therapies should be further investigated.https://www.frontiersin.org/articles/10.3389/fmolb.2021.812101/fullcystic fibrosisCFTR modulatorsVX-661 correctorprolonged chronic treatmentHGF
spellingShingle Ana M. Matos
Ana M. Matos
Peter Jordan
Peter Jordan
Paulo Matos
Paulo Matos
Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
Frontiers in Molecular Biosciences
cystic fibrosis
CFTR modulators
VX-661 corrector
prolonged chronic treatment
HGF
title Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
title_full Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
title_fullStr Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
title_full_unstemmed Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
title_short Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770
title_sort treatment of polarized cystic fibrosis airway cells with hgf prevents vx 661 rescued f508del cftr destabilization caused by prolonged co exposure to vx 770
topic cystic fibrosis
CFTR modulators
VX-661 corrector
prolonged chronic treatment
HGF
url https://www.frontiersin.org/articles/10.3389/fmolb.2021.812101/full
work_keys_str_mv AT anammatos treatmentofpolarizedcysticfibrosisairwaycellswithhgfpreventsvx661rescuedf508delcftrdestabilizationcausedbyprolongedcoexposuretovx770
AT anammatos treatmentofpolarizedcysticfibrosisairwaycellswithhgfpreventsvx661rescuedf508delcftrdestabilizationcausedbyprolongedcoexposuretovx770
AT peterjordan treatmentofpolarizedcysticfibrosisairwaycellswithhgfpreventsvx661rescuedf508delcftrdestabilizationcausedbyprolongedcoexposuretovx770
AT peterjordan treatmentofpolarizedcysticfibrosisairwaycellswithhgfpreventsvx661rescuedf508delcftrdestabilizationcausedbyprolongedcoexposuretovx770
AT paulomatos treatmentofpolarizedcysticfibrosisairwaycellswithhgfpreventsvx661rescuedf508delcftrdestabilizationcausedbyprolongedcoexposuretovx770
AT paulomatos treatmentofpolarizedcysticfibrosisairwaycellswithhgfpreventsvx661rescuedf508delcftrdestabilizationcausedbyprolongedcoexposuretovx770